Structure Therapeutics (NASDAQ:GPCR – Get Free Report) and IN8bio (NASDAQ:INAB – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.
Earnings & Valuation
This table compares Structure Therapeutics and IN8bio”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Structure Therapeutics | N/A | N/A | -$141.20 million | ($0.87) | -59.47 |
| IN8bio | N/A | N/A | -$19.44 million | ($2.61) | -0.52 |
Volatility & Risk
Structure Therapeutics has a beta of -1.5, suggesting that its stock price is 250% less volatile than the S&P 500. Comparatively, IN8bio has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500.
Insider & Institutional Ownership
91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 92.1% of IN8bio shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by insiders. Comparatively, 14.5% of IN8bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Structure Therapeutics and IN8bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Structure Therapeutics | N/A | -24.91% | -23.67% |
| IN8bio | N/A | -96.39% | -80.18% |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Structure Therapeutics and IN8bio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Structure Therapeutics | 2 | 1 | 12 | 3 | 2.89 |
| IN8bio | 1 | 1 | 1 | 0 | 2.00 |
Structure Therapeutics presently has a consensus target price of $110.55, indicating a potential upside of 113.65%. IN8bio has a consensus target price of $4.00, indicating a potential upside of 196.30%. Given IN8bio’s higher possible upside, analysts plainly believe IN8bio is more favorable than Structure Therapeutics.
About Structure Therapeutics
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager
platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications.
Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
